• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮血运重建治疗稳定型冠状动脉疾病的时间趋势及药物洗脱支架的影响

Percutaneous revascularization for stable coronary artery disease temporal trends and impact of drug-eluting stents.

机构信息

Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.

出版信息

JACC Cardiovasc Interv. 2010 Feb;3(2):172-9. doi: 10.1016/j.jcin.2009.11.013.

DOI:10.1016/j.jcin.2009.11.013
PMID:20170874
Abstract

OBJECTIVES

We sought to determine the characteristics, outcomes, and temporal trends among patients undergoing percutaneous coronary intervention (PCI) for stable coronary artery disease (CAD) from a single-center registry.

BACKGROUND

There is controversy regarding the generalizability of the findings from randomized trials of PCI for stable CAD to daily practice. An important perspective on the significance of the trial results can be achieved by clearly documenting past and present practice of PCI.

METHODS

This was a retrospective analysis of 8,912 consecutive patients undergoing elective PCI from 1979 through 2006 at a tertiary referral center. Clinical, angiographic, and procedural characteristics as well as in-hospital and long-term outcomes were measured in patients grouped into 4 eras depending on the dominant interventional strategy of that time: percutaneous transluminal coronary angioplasty, early stent, bare-metal stent, and drug-eluting stent.

RESULTS

Procedural success rates have improved (81%, 92%, 96%, and 97%, respectively, p < 0.001), and in-hospital mortality has decreased significantly (1.0%, 0.8%, 0.1%, and 0.1%, respectively, p < 0.001) over time. Kaplan-Meier estimates of mortality at 4 years were 11%, 13%, 10%, and 10%, respectively (p = 0.4). The 1-year target lesion revascularization rates in the 4 groups were 29%, 26%, 13%, and 8%, respectively (p < 0.001).

CONCLUSIONS

Procedural success rates in contemporary practice of PCI for stable CAD are excellent with very low in-hospital mortality. Introduction of drug-eluting stents has reduced target lesion revascularization but not mortality among all comers. Outcomes similar to that observed in recent clinical trials are being achieved in routine clinical practice.

摘要

目的

我们旨在从单中心注册研究中确定经皮冠状动脉介入治疗(PCI)稳定型冠状动脉疾病(CAD)患者的特征、结局和时间趋势。

背景

随机 PCI 治疗稳定 CAD 试验结果的普遍性存在争议,对 PCI 实践的过去和现在进行明确记录可以更清楚地了解试验结果的重要意义。

方法

这是对 1979 年至 2006 年在一家三级转诊中心行择期 PCI 的 8912 例连续患者进行的回顾性分析。根据当时主导的介入策略,将患者分为 4 个时期,测量临床、血管造影和手术特征以及住院和长期结局:经皮腔内冠状动脉成形术、早期支架、裸金属支架和药物洗脱支架。

结果

手术成功率不断提高(分别为 81%、92%、96%和 97%,p < 0.001),住院死亡率显著下降(分别为 1.0%、0.8%、0.1%和 0.1%,p < 0.001)。4 年时死亡率的 Kaplan-Meier 估计值分别为 11%、13%、10%和 10%(p = 0.4)。4 组的 1 年靶病变血运重建率分别为 29%、26%、13%和 8%(p < 0.001)。

结论

在稳定型 CAD 的现代 PCI 实践中,手术成功率非常高,住院死亡率极低。药物洗脱支架的应用降低了所有患者的靶病变血运重建率,但没有降低死亡率。在常规临床实践中,正在取得与最近临床试验相似的结果。

相似文献

1
Percutaneous revascularization for stable coronary artery disease temporal trends and impact of drug-eluting stents.经皮血运重建治疗稳定型冠状动脉疾病的时间趋势及药物洗脱支架的影响
JACC Cardiovasc Interv. 2010 Feb;3(2):172-9. doi: 10.1016/j.jcin.2009.11.013.
2
Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.性别对既往未经治疗的冠状动脉疾病患者使用裸金属支架和药物洗脱支架进行经皮冠状动脉介入治疗后3年预后的影响:来自RESEARCH(鹿特丹心脏病医院雷帕霉素洗脱支架评估)和T-SEARCH(鹿特丹心脏病医院紫杉醇支架评估)注册研究的见解
JACC Cardiovasc Interv. 2009 Jul;2(7):603-10. doi: 10.1016/j.jcin.2009.03.016.
3
The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.SYNTAX 评分对依维莫司和佐他莫司洗脱支架血运重建后 1 年结局的预后价值:RESOLUTE 所有患者试验的一项亚组研究。
JACC Cardiovasc Interv. 2011 Apr;4(4):432-41. doi: 10.1016/j.jcin.2011.01.008.
4
The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.在 6 年随访期间,无限制使用西罗莫司和紫杉醇洗脱支架的临床结果优于裸金属支架:对 RESEARCH(雷帕霉素洗脱支架在鹿特丹心脏病学医院评估)和 T-SEARCH(紫杉醇洗脱支架在鹿特丹心脏病学医院评估)注册研究的分析。
JACC Cardiovasc Interv. 2010 Oct;3(10):1051-8. doi: 10.1016/j.jcin.2010.08.003.
5
Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.比较西罗莫司和紫杉醇洗脱支架与裸金属支架经皮治疗稳定型冠状动脉疾病的 4 年临床结果。
Catheter Cardiovasc Interv. 2010 Jul 1;76(1):41-9. doi: 10.1002/ccd.22533.
6
Long-term paclitaxel-eluting stent outcomes in elderly patients.老年患者中长期紫杉醇洗脱支架的结果。
Circ Cardiovasc Interv. 2009 Jun;2(3):178-87. doi: 10.1161/CIRCINTERVENTIONS.109.855221. Epub 2009 Jun 2.
7
Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients.透析患者使用药物洗脱支架与裸金属支架进行经皮冠状动脉介入治疗后的临床结局
J Invasive Cardiol. 2006 Dec;18(12):577-83.
8
Long-term outcome of percutaneous coronary intervention for chronic total occlusions.经皮冠状动脉介入治疗慢性完全闭塞病变的长期结果。
JACC Cardiovasc Interv. 2011 Sep;4(9):952-61. doi: 10.1016/j.jcin.2011.03.021.
9
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).在冠状动脉疾病中,依维莫司洗脱支架与紫杉醇洗脱支架的荟萃分析:SPIRIT 临床试验计划的最终 3 年结果(在治疗新发病变的患者中,使用依维莫司洗脱冠状动脉支架系统治疗的西里斯 V 依维莫司洗脱冠状动脉支架系统的临床评估)。
JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005.
10
Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.经皮冠状动脉介入治疗开口/中段病变与无保护左主干冠状动脉分叉病变的长期临床结局:DELTA 注册研究(左主干冠状动脉疾病药物洗脱支架):一项多中心注册研究,评估经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗左主干的疗效。
JACC Cardiovasc Interv. 2013 Dec;6(12):1242-9. doi: 10.1016/j.jcin.2013.08.005.

引用本文的文献

1
Incidence and Long-Term Outcomes of Stroke in Patients Presenting With ST-Segment Elevation-Myocardial Infarction: Insights From the Midwest STEMI Consortium.ST 段抬高型心肌梗死患者的卒中发生率和长期预后:来自中西部 STEMI 联盟的研究结果。
J Am Heart Assoc. 2021 Dec 7;10(23):e022489. doi: 10.1161/JAHA.121.022489. Epub 2021 Nov 24.
2
Current Indications for Stenting: Symptoms or Survival .支架置入的当前适应证:症状或生存
Methodist Debakey Cardiovasc J. 2018 Jan-Mar;14(1):7-13. doi: 10.14797/mdcj-14-1-7.
3
Revascularization and outcomes in Veterans with moderate to severe ischemia on myocardial perfusion imaging.
心肌灌注成像显示中重度缺血的退伍军人的血运重建和结局。
Mil Med Res. 2017 Apr 1;4:12. doi: 10.1186/s40779-017-0121-x. eCollection 2017.
4
Reexamining the Efficacy and Value of Percutaneous Coronary Intervention for Patients With Stable Ischemic Heart Disease.重新评估经皮冠状动脉介入治疗稳定型缺血性心脏病患者的疗效和价值。
JAMA Intern Med. 2016 Aug 1;176(8):1190-4. doi: 10.1001/jamainternmed.2016.3071.
5
Temporal trends in mortality after coronary artery revascularization in patients with end-stage renal disease.终末期肾病患者冠状动脉血运重建术后死亡率的时间趋势。
Perm J. 2014 Summer;18(3):11-6. doi: 10.7812/TPP/14-003.
6
The decline effect in cardiovascular medicine: is the effect of cardiovascular medicine and stent on cardiovascular events decline over the years?心血管医学中的下降效应:心血管药物和支架对心血管事件的影响是否随着时间的推移而下降?
Korean Circ J. 2013 Jul;43(7):443-52. doi: 10.4070/kcj.2013.43.7.443.
7
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.慢性稳定型心绞痛治疗的最新进展II. 抗缺血治疗、难治性心绞痛的治疗选择、危险因素的降低及血运重建
Vasc Health Risk Manag. 2010 Sep 7;6:749-74. doi: 10.2147/vhrm.s11100.